Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

Next Previous
X
Search
Trial Profile

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glecirasib (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Carcinoma; Cervical cancer; Colorectal cancer; Ductal carcinoma; Gastric cancer; Liver cancer; Mediastinal disorders; Non-small cell lung cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Sponsors Jacobio Pharmaceuticals

    • Most Recent Events

    • 12 Jun 2024 Planned number of patients changed from 144 to 311.
    • 12 Jun 2024 Status changed from recruiting to active, no longer recruiting.
    • 30 Apr 2024 Results published in the Jacobio Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top